NCT05737082View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

May 14, 2023

Study Completion Date

May 14, 2023

Conditions
Healthy
Interventions
DRUG

HCP2201

Take 2 tablets once per period

DRUG

RLD2205

Take 2 tablets once per period

DRUG

RLD2206

Take 1 tablet once per period

Trial Locations (1)

Unknown

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05737082 - A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers | Biotech Hunter | Biotech Hunter